Alvocidib - Small Molecule (ID:10011-101)
| HMS LINCS ID: |
10011-101
|
| Name: | Alvocidib |
| Alternative Names: | Flavopiridol; HMR-1275; L868275 |
| LINCS ID: | LSM-1011 |
| PubChem CID: | 5287969 |
| ChEBI ID: | |
| ChEMBL ID: | 428690 |
| Molecular Mass: | 401.10 |
| InChi: | InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1 |
| InChi Key: | BIIVYFLTOXDAOV-YVEFUNNKSA-N |
| SMILES: | CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O |
| Relevant Citations: | |
| Comments: | |
| Date Publicly Available: | |
| Most Recent Update: | 2016-07-12 |
Target Affinity:
(see Study 20000)| Target Affinity Spectrum Value | HUGO Gene Name |
|---|---|
CAMKK1, CCNB1, CCNT1, CDK1, CDK19, CDK4, CDK6, CDK7, CDK9, CDKL5, DYRK1A, DYRK1B, FPGT-TNNI3K, ICK, MAK, MAP4K2, TAOK3, TNNI3K, VRK2 | |
2 (equivalent to 100 nM ≤ Kd < 1µM) | ALK, BMPR1B, CAMKK2, CCNA1, CCNA2, CCNB2, CCNB3, CCND1, CCND2, CCND3, CCNE1, CCNE2, CCNH, CDK13, CDK14, CDK15, CDK16, CDK17, CDK2, CDK3, CDK5, CDK5R1, CDK8, CDKN3, CIT, DMPK, Dyrk1a, EIF2AK1, GAK, GRK1, GRK7, GSK3B, IRAK1, MAP2K5, MAPK15, MAPK7, PIM1, PIM2, PIM3, PIP4K2C, PRKCD, PRKCE, PRKCH, PRKCQ, PRKD1, PRKD3, STK35, TAOK1, TAOK2, TBK1, TYK2, ULK2 |
3 (equivalent to 1µM ≤ Kd < 10 µM) | AAK1, ABL1, ACVR1, ACVR2A, ACVR2B, ACVRL1, AXL, CAMK2A, CAMK2B, CAMK2D, CAMK2G, CAMK4, CDC42BPA, CDC42BPB, CDK18, Clk1, CLK1, CLK2, CLK3, CSF1R, CSNK1A1, CSNK1A1L, CSNK1G1, DCLK1, DCLK3, DSTYK, EGFR, EIF2AK2, EPHA1, EPHA2, EPHA3, EPHA5, EPHB1, ERBB3, ERBB4, FLT3, FRK, GSK3A, HIPK1, HIPK2, HIPK3, HIPK4, IKBKE, IRAK4, JAK2, JAK3, KIT, LRRK2, LTK, MAP2K3, MAP2K4, MAP3K10, MAP3K2, MAP3K3, MAP3K7, MAP3K9, MAP4K1, MAP4K3, MAPK10, MAPK8, MERTK, MINK1, MKNK2, NUAK2, PDGFRA, PF3D7_1356900, PHKG1, PHKG2, PIP5K1C, PKD1, PKD2, PKN1, PLK4, PRKD2, PTK2B, PYGM, PYGM, ROCK1, ROCK2, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6, RPS6KB1, SRMS, STK17A, STK17B, STK3, STK32A, STK33, TGFBR2 |
10 (confirmed non-binding) |
Datasets:
| HMS Dataset ID | Dataset Title | HMS Dataset Type |
|---|---|---|
| 20000 | Target Affinity Spectrum (TAS) vectors for compounds in the HMS LINCS small molecule library. | Analysis |
| 20237 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. | Microscopy/Imaging |
| 20238 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. | Microscopy/Imaging |
| 20239 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. | Microscopy/Imaging |
| 20240 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. | Microscopy/Imaging |
| 20241 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. | Microscopy/Imaging |
| 20242 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. | Microscopy/Imaging |
| 20243 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 7 of 15: Mean cell count and mean growth rate across all replicates. | Microscopy/Imaging |
| 20245 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. | Microscopy/Imaging |
| 20246 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. | Microscopy/Imaging |
| 20247 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. | Microscopy/Imaging |
| 20248 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. | Microscopy/Imaging |
| 20249 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. | Microscopy/Imaging |
| 20250 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. | Microscopy/Imaging |
| 20251 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 14 of 15: Mean cell count and mean normalized growth rate inhibition values across all replicates. | Microscopy/Imaging |
| 20252 | LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 15 of 15: Calculated dose-response metrics. | Analysis |
| 20354 | Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values | Microscopy/Imaging |
| 20355 | Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics | Analysis |
| 20369 | Binding affinity of 6 small molecule JAK inhibitors for 5 kinases | Affinity Data |
| 20373 | DGE-seq Gene expression data for 7 breast cancer cell lines treated with abemaciclib, palbociclib, ribociclib at 0.1, 0.3, 1, or 3 μM, or alvocidib at 0.1 or 1 μM for 6 hours | RNA-Seq |
Batch Information:
| HMS LINCS Batch ID | Provider | Provider Batch ID |
|---|---|---|
| 10011-101-1 | Haoyuan chemexpress | HY-009_TM-20090429 |
(Kd <100 nM)